Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 16/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 15/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089769 | 0.87 | PRMT5 (0.40) | PRMT5WDR77 | |
| SCHEMBL18572831 | 0.85 | PRMT5 (0.52) | PRMT5WDR77ADK | |
| SCHEMBL18571936 | 0.84 | PRMT5 (0.53) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL26813322 | 0.81 | ADK (0.64) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL9915115 | 0.81 | PI4KA (0.55) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL22334075 | 0.80 | PI4KA (0.69) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL22434784 | 0.80 | PI4KA (0.69) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL22334076 | 0.80 | PI4KA (0.69) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL15397029 | 0.80 | PI4KA (0.69) | PRMT5WDR77ADKRAPGEF3PI4KA | |
| SCHEMBL24293844 | 0.79 | ADK (0.52) | ADKRAPGEF3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020243178-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 236/4885ADK 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.